Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin surrogates in insulinoma

T O'Brien1, P C O'Brien, F J Service

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.

The Journal of Clinical Endocrinology and Metabolism
|August 1, 1993
PubMed
Summary

Diagnosing insulinoma can be challenging due to unclear hyperinsulinemia criteria. This study identifies key metabolic markers, like beta-hydroxybutyrate and glucose response to glucagon, as reliable indicators of insulinoma, especially when glucose levels are low.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atrophy rates accelerate in amnestic mild cognitive impairment.

Neurology·2007
Same author

The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

Diabetes care·2006
Same author

Chromosome painting and molecular dating indicate a low rate of chromosomal evolution in golden moles (Mammalia, Chrysochloridae).

Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology·2006
Same author

Polyneuropathy dysfunction scores.

Journal of neurology, neurosurgery, and psychiatry·2006
Same author

Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.

Neurology·2005
Same author

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.

Neurology·2005

Area of Science:

  • Endocrinology
  • Metabolic Research
  • Oncology

Background:

  • Establishing definitive diagnostic criteria for hyperinsulinemia in insulinoma remains a clinical challenge.
  • Existing diagnostic methods may lack sensitivity in specific patient subgroups, necessitating surrogate markers for insulin action.

Purpose of the Study:

  • To identify reliable surrogate measures of insulin action for assessing hyperinsulinemia in suspected insulinoma.
  • To evaluate the diagnostic utility of plasma beta-hydroxybutyrate, free fatty acids (FFA), and plasma glucose response to intravenous glucagon as indicators of hyperinsulinemia.

Main Methods:

  • Prospective study involving 40 patients with histologically confirmed insulinoma and 25 healthy controls.
  • Measurements included plasma beta-hydroxybutyrate, FFA, plasma glucose response to intravenous glucagon, plasma insulin, and C-peptide levels after a prolonged fast.

Main Results:

  • Patients with insulinoma exhibited significantly lower plasma beta-hydroxybutyrate and FFA levels compared to controls.
  • A significantly greater plasma glucose response to intravenous glucagon was observed in insulinoma patients.
  • Plasma glucose response to glucagon and plasma beta-hydroxybutyrate effectively distinguished insulinoma from controls, particularly when plasma glucose was ≤ 3.3 mmol/L, outperforming insulin and C-peptide levels.

Conclusions:

  • Plasma glucose response to intravenous glucagon (≥ 1.4 mmol/L) and plasma beta-hydroxybutyrate (≤ 2.7 mmol/L) are valuable indicators of insulinoma-associated hyperinsulinemia when plasma glucose is ≤ 3.3 mmol/L.
  • These metabolic surrogates offer superior diagnostic accuracy over plasma insulin and C-peptide in specific low-glucose scenarios.
  • The findings provide improved diagnostic tools for insulinoma, addressing limitations in current hyperinsulinemia assessment.

Related Experiment Videos